CA2348844A1 - Composes et ses utilisations therapeutiques dans la prevention de complications d'un diabetique - Google Patents

Composes et ses utilisations therapeutiques dans la prevention de complications d'un diabetique Download PDF

Info

Publication number
CA2348844A1
CA2348844A1 CA002348844A CA2348844A CA2348844A1 CA 2348844 A1 CA2348844 A1 CA 2348844A1 CA 002348844 A CA002348844 A CA 002348844A CA 2348844 A CA2348844 A CA 2348844A CA 2348844 A1 CA2348844 A1 CA 2348844A1
Authority
CA
Canada
Prior art keywords
group
lysine
carcinoma
unsubstituted
fructose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002348844A
Other languages
English (en)
Inventor
Truman R. Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fox Chase Cancer Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2348844A1 publication Critical patent/CA2348844A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne une classe de composés inhibant la conversion enzymatique de fructose-lysine en fructose-lysine-3-phosphate dans une réaction dépendante de l'ATP dans une voie métabolique nouvellement découverte. Selon le fonctionnement normal de cette voie, le fructose-lysine-3-phosphate (FL3P) est décomposé en une lysine de forme libre, en phosphate inorganique et en 3-désoxyglucosone (3DG), cette dernière étant un agent modifiant une protéine réactive. La 3DG peut être détoxifiée par réduction en 3-désoxyfructose (3DF), ou elle peut réagir avec des protéines endogènes pour former des protéines modifiées par un produit final de glycation avancée (protéines AGE), dont on croit qu'elles sont une cause participant à des complications diabétiques. L'invention concerne également des méthodes thérapeutiques d'utilisation de ces inhibiteurs pour réduire la formation de protéines AGE et ainsi amoindrir, réduire ou retarder les complications diabétiques, de même que des méthodes d'évaluation du risque d'un diabétique de développer des complications, et de détermination de l'efficacité de la thérapie par inhibiteurs décrite, par mesure du rapport entre 3DG et 3DF dans un échantillon biologique après administration d'une dose orale d'un produit alimentaire à base de fructose-lysine.
CA002348844A 1998-10-28 1999-10-28 Composes et ses utilisations therapeutiques dans la prevention de complications d'un diabetique Abandoned CA2348844A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18211498A 1998-10-28 1998-10-28
US09/182,114 1998-10-28
PCT/US1999/025358 WO2000024405A1 (fr) 1998-10-28 1999-10-28 Composes et ses utilisations therapeutiques dans la prevention de complications d'un diabetique

Publications (1)

Publication Number Publication Date
CA2348844A1 true CA2348844A1 (fr) 2000-05-04

Family

ID=22667112

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002348844A Abandoned CA2348844A1 (fr) 1998-10-28 1999-10-28 Composes et ses utilisations therapeutiques dans la prevention de complications d'un diabetique

Country Status (7)

Country Link
EP (1) EP1126856A4 (fr)
JP (1) JP2002528419A (fr)
CN (1) CN1331599A (fr)
AU (1) AU773401C (fr)
CA (1) CA2348844A1 (fr)
HK (1) HK1042253A1 (fr)
WO (1) WO2000024405A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140069A0 (en) * 1998-06-11 2002-02-10 Fox Chase Cancer Ct A method for assessing a diabetic's risk of experiencing a diabetes-associated pathologic condition
EP1175155A4 (fr) * 1999-04-15 2005-10-19 Fox Chase Cancer Ct Procede destine a reduire la predisposition a la formation de tumeurs provoquees par la 3-desoxyglucosone et les precurseurs de cette substance
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
CN104768544B (zh) * 2012-08-09 2017-06-16 迪纳米斯治疗公司 包括葡甲胺或其盐的组合物在制备减少或预防甘油三酯水平增加的药物中的应用
CN111638363B (zh) * 2020-04-30 2022-02-18 吉林省格瑞斯特生物技术有限公司 3-脱氧果糖快速定量荧光检测装置及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484735A (en) * 1989-08-23 1996-01-16 Northwestern University Immunoassay of glycosylated proteins employing antibody directed to reductively glycosylated N-terminal amino acids
JP3124028B2 (ja) * 1989-08-23 2001-01-15 ノースウェスターン ユニヴァーシティ 還元的にグリコシル化されたｎ―末端アミノ酸に向けられた抗原を使用するグリコシル化されたタンパクの免疫学的測定法
JPH07500580A (ja) * 1991-09-09 1995-01-19 ペプテック　リミテッド 糖尿病の合併症及び病因の処理方法
JPH0733667A (ja) * 1992-07-03 1995-02-03 Japan Tobacco Inc ４，６−ｏ−ヒドロキシホスホリルグルコサミン誘導体の水溶液及び水溶化方法
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6004958A (en) * 1997-02-05 1999-12-21 Fox Chase Cancer Center Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
AU6518598A (en) * 1997-03-28 1998-10-22 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b6

Also Published As

Publication number Publication date
AU773401B2 (en) 2004-05-27
CN1331599A (zh) 2002-01-16
HK1042253A1 (zh) 2002-08-09
EP1126856A4 (fr) 2008-05-14
WO2000024405A9 (fr) 2000-10-19
EP1126856A1 (fr) 2001-08-29
AU773401C (en) 2005-04-28
WO2000024405A1 (fr) 2000-05-04
AU1709400A (en) 2000-05-15
JP2002528419A (ja) 2002-09-03

Similar Documents

Publication Publication Date Title
CA2279428C (fr) Composes et procedes concernant l'utilisation d'agents therapeutiques dans la prevention de complications diabetiques
US8431527B2 (en) Methods for alleviating deleterious effects of 3-deoxyglucosone
AU773401C (en) Compounds and their therapeutic use with diabetic complications
AU743112B2 (en) Method for assessing a diabetic's risk of experiencing a diabetes-associated pathologic condition
CA2455805C (fr) Composes et procedes concernant l'utilisation d'agents therapeutiques dans la prevention de complications diabetiques
Mackay et al. Pharmacokinetics and anti‐hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1, 4‐dideoxy‐1, 4‐imino‐d‐arabinitol, in glucagon‐challenged rats and dogs and in diabetic ob/ob mice
Szwergold α-Thiolamines such as cysteine and cysteamine act as effective transglycating agents due to formation of irreversible thiazolidine derivatives
US8138227B2 (en) Method for inhibiting or reversing non-enzymatic glycation
US6265442B1 (en) Treatment of neurological diseases by increasing brain concentrations of kynurenic acid
Krooth et al. Effect of 6-azauracil, and of certain structurally similar compounds, on three pyridoxal-phosphate requiring enzymes involved in neurotransmitter metabolism
WILSON et al. Investigation of the 5-hydroxylation of thiabendazole in rat liver microsomal preparations
Baba et al. Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial
Böckelmann et al. Influence of nitric oxide synthase activity on amino acid concentration in the quinolinate lesioned rat striatum: A microdialysis and histochemical study
Nyström On endothelial function in type 2 diabetic patients with coronary artery disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead